The Latest in FDA Evaluations and Research

FDA News


Latest News from FDA News
RALEIGH, NC--(Marketwired - September 03, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage s...
PetLife Pharmaceuticals, Inc. (PINKSHEETS: EVGI) (PINKSHEETS: EVGID), today issued the following Special Letter to Shareholders from its Founder and Chief Executive Officer, Arthur G. Mikaelian, Ph.D.
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, ...
BOTHELL, Wash., Sept. 3, 2014 /PRNewswire/ -- Alpinion Medical Systems, a leader in the development of diagnostic ultrasound, transducers, and HIFU, unveiled its innovative E-CUBE 12R clinical research platform at the 2014 IEEE International Ultrasonics Symposium (Booth #413) in Chicag...
GE Healthcare (NYSE: GE) today announced the FDA approval of SenoClaire*, GE’s new breast tomosynthesis solution designed with a three-dimensional imaging technology. In collaboration with Massachusetts General Hospital, GE developed SenoClaire technology th...
SUNNYVALE, Calif., Sept. 3, 2014 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of Xpert® TV, an on-demand molecular test for rapid, accurate and reproducible identification of Trichomoniasis (TV) infections in both males and females. The test will be marketed as a ...
RALEIGH, N.C., Sept. 3, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the company will visit the NASDAQ MarketSite in Times Square on September 4, 2014.  In honor of the occasion, Dr. Mark A. Sirgo, President and Chief Executive Officer of ...
ST. PAUL, Minn., Sept. 3, 2014 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of results from the Company's ReCh...
-- First molecular test indicated for samples from both males and females
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the minutes from its meeting with the U.S. Food and Drug Administration (FDA) in July confirmed that the Company's existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emer...
TUCSON, Ariz., Sept. 3, 2014 /PRNewswire/ -- With the help of the SynCardia temporary Total Artificial Heart, Patrick "Pat" O'Hara was bridged to a donor heart transplant and beat genetic heart failure that claimed the lives of two siblings and caused a third to have a heart attack.
CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., Sept. 3, 2014 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibi...
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA") for its anti-fibrotic, lead drug candidate, PBI-4050.
ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") announced today it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA") for its anti-fibrotic, lead drug candidate, PBI-4050.
SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate issued by the Medicines and Healthcare produc...
A second independent lab test provided further evidence that the Catheter Connections DualCap products for male luers fail to consistently disinfect the tip of the male luer connector. Ivera Medical sued Catheter Connections for false advertising and unfair competition last week based ...
CRANBURY, N.J. and BUDAPEST, Hungary, Sept. 3, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") announced that they have entered into a collaboration and license agreement to co-develop and commerci...
Vivione Biosciences Inc. (“Vivione”) (TSXV:VBI), through its wholly owned subsidiary, Vivione Biosciences, LLC, launched its Petro Chemical Bio-Diagnostics (“PC Bio”) bacterial identification and enumeration solution this past week at the Unconventional Reso...
LONDON, Sept. 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administrationhttps://www.reportbuyer.com/product/1941928/Global-Markets-and-Technologies-for-Advanced-D...
LONDON, Sept. 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Picoprojectors: Technologies and Global Marketshttps://www.reportbuyer.com/product/1863186/Picoprojectors-Technologies-and-Global-Markets.htmlSTUDY GOALS AND OBJECTIVESThe primary goal of this ...
LONDON, Sept. 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
DENVER, Sept. 2, 2014 /PRNewswire/ -- The Annals of Internal Medicine just published results of a National Institutes of Health (NIH) trial titled "Effects of low-carbohydrate and low-fat diets," in which a low-carbohydrate diet was found to be more effective both for weight loss and c...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on September 3, 2014, it will report the outcome of the Company's July meeting with the U.S. Food and Drug Administration (FDA), and will host a conference call at 11:00 a.m. ET.
AUSTIN, Texas, Sept. 2, 2014 /PRNewswire/ -- On July 31, the Food and Drug Administration sent its 60-day notice to Congress that it is moving forward to regulate laboratory-developed tests (LDTs). The clock is now ticking down the minutes until laboratories throughout the U.S. will ne...
CHICAGO, Sept. 2, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) launches a full month of events and initiatives for September's Global Pulmonary Fibrosis (PF) Awareness Month, starting with a proclamation by Chicago's mayor; surpassing a milestone in collectin...
AUSTIN, Texas, Sept. 2, 2014 /PRNewswire/ -- XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix™.
MIAMI, Sept. 2, 2014 /PRNewswire-USNewswire/ -- U.S. Senate Resolution 533, introduced by Senator Marco Rubio of Florida, designates September 2014 as "National Spinal Cord Injury Awareness Month". This designation is especially timely given the progress being made toward a cure for sp...
ELK GROVE VILLAGE, Ill., Sept. 2, 2014 /PRNewswire-USNewswire/ -- Families of SMA, founded in 1984 by a small group of families affected by spinal muscular atrophy (SMA), has announced that the organization will become Cure SMA. Spinal muscular atrophy is a motor neuron disease that af...
NEW YORK, September 2, 2014 /PRNewswire/ --
NEW YORK, September 2, 2014 /PRNewswire/ --
DRAPER, Utah, Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® Corporation (ODEV) has received FDA clearance for the Alpine™ Hip Stem, the latest addition to its growing hip replacement product line. The Alpine Hip Stem is intended for use in total hip arthroplasty and hemiarthr...
CAMBRIDGE, England and BOSTON, Sept. 2, 2014 /PRNewswire/ -- Today, Linguamatics I2E Semantic Enrichment has been selected as a KMWorld 2014 Trend-Setting Product. I2E Semantic Enrichment, the newest offering from Linguamatics, is used within an existing enterprise search deployment to...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review boar...
DUBLIN, Sept. 2, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men an...